GLP-1 prices in 2027: what is already decided
On January 1, 2027, Medicare starts paying $274 for 30 days of Ozempic, Wegovy or Rybelsus, and the Part D cap rises to $2,400.
Several GLP-1 price changes for 2027 are already published, and they pull in different directions. For Medicare, the negotiated price of semaglutide, $274 for a 30-day supply of Ozempic, Wegovy or Rybelsus, takes effect on January 1, 2027, according to the CMS file dated September 21, 2026. At the same time the Part D standard benefit moves: the maximum deductible rises from $615 to $700 and the out-of-pocket cap from $2,100 to $2,400. For Ozempic the net effect is a lower yearly share, about $1,347 against $2,100; for a GLP-1 without a negotiated price, such as Mounjaro, the higher cap means paying up to $300 more. In the cash channel, Novo Nordisk’s $199 starter offer and Lilly’s reduced prices for Foundayo 2.5 and 5.5 mg are scheduled to end on December 31, 2026. The Medicare GLP-1 Bridge continues at $50 a month through December 31, 2027.
2026 against 2027 for one drug
Change from 2026 to 2027
−$753
| 2026 | $2,100 |
| 2027 | $1,347 |
2027 uses CMS negotiated prices and Part D parameters already published; cash prices are today’s unless an end date is announced.
Prices read by Radif Partners · Editorial policy · Method and data
Scheduled changes, one by one
| Item | 2026 | 2027 | Source |
|---|---|---|---|
| Medicare price, semaglutide (30 days) | plan price | $274 | CMS negotiated prices |
| Part D deductible, at most | $615 | $700 | CMS 2027 Rate Announcement |
| Part D out-of-pocket cap | $2,100 | $2,400 | CMS 2027 Rate Announcement |
| Extra Help, brand copay | $12.65 | $14.40 | CMS 2027 Rate Announcement |
| Medicare GLP-1 Bridge | $50 from July 1 | $50 to December 31 | CMS Bridge FAQ |
| Wegovy and Ozempic starter offer | $199 for two fills | ends December 31, 2026 | NovoCare terms |
| Foundayo 2.5 mg / 5.5 mg | $149 / $199 | $199 / $299 | LillyDirect terms |
What is not decided
Self-pay prices beyond these end dates are the manufacturers’ to set; nothing published says whether the regular Wegovy, Zepbound or Ozempic cash prices will move in 2027, so the calculator keeps today’s regular prices for 2027 and says so. The BALANCE Model will not launch in Part D in 2027, CMS says, and which states adopt it in Medicaid is not yet public. The negotiated prices of the fifteen drugs selected for 2028, Trulicity among them, are not out yet.
Who gains, who pays more
A Medicare enrollee on Ozempic, Wegovy for heart risk, or Rybelsus pays less in 2027 under the standard benefit. One on Mounjaro or Zepbound for sleep apnea, with no negotiated price, can pay $300 more because the cap is higher. A new cash patient starting Wegovy in 2027 loses the starter discount, $300 over the first two months. A Bridge user pays the same $50 a month all year.
How we keep this current
The prices on this site are refreshed from TrumpRx, NADAC and the CMS files every week by an automated job; the rules in this table are checked by hand each month and dated at the foot of the page.
The negotiated price in practice
From January 1, 2027, a Part D plan that covers Ozempic, Wegovy or Rybelsus pays the negotiated price of $274 for any 30-day supply, whatever the strength. Pharmacies buy the drug at the usual price and are made whole by the manufacturer for the difference, through a system CMS set up for the program. For the enrollee, the visible change depends on the plan’s design. On coinsurance, 25% of $274 is $69 a month after the deductible, against a quarter of a price close to a thousand dollars in 2026. On a flat copay, the monthly amount may not move at all; the saving shows up in the plan’s costs and, indirectly, in premiums.
Two drugs leave, fifteen arrive
The 2027 list adds fifteen drugs, from Trelegy Ellipta and Breo Ellipta for lung disease to Xtandi and Ibrance for cancer and Janumet and Tradjenta for diabetes; their prices are in the negotiated prices table. Some 2026 drugs have no 2027 line in the CMS file, which means plans will pay their own price for them again. The $2,400 cap protects enrollees either way, but someone whose drug leaves the program can see a higher share in the first months of 2027.
What to watch in the coming months
Three publications will change this page: the prices of the fifteen drugs selected for 2028, which CMS negotiates during 2026; any announcement by Novo Nordisk or Lilly extending or replacing their starter and temporary prices beyond December 31, 2026; and the list of states that join the BALANCE Model for Medicaid. Our weekly data job picks up price files automatically; announcements are checked by hand each month.